AstraZeneca Pharma India Limited has set up its new corporate office in Mumbai, marking an extension of company’s presence in India, reinforcing its ambition to transforming care by unlocking the power of science. The new office spread across 25,600 sq ft.
The company has introduced more than 25 new medicines and indications in India over the past three years and is currently running about 80 global clinical trials in the country, supporting the development of new treatments, strengthening India’s contribution to global research and getting the right medicines to the right patients, faster.
Maharashtra chief minister Devendra Fadnavis, said “Maharashtra has a strong and growing pharmaceutical and life sciences ecosystem, supported by skilled talent, leading institutions and robust healthcare infrastructure. AstraZeneca’s decision to establish its India commercial office in Mumbai reflects confidence in the state’s capabilities and its potential as an innovation hub. We welcome AstraZeneca’s continued commitment to Maharashtra and look forward to the opportunities this will create for collaboration, capability building and skilled employment.”
“India is at an important inflection point in healthcare, with a growing need for earlier diagnosis, innovative treatments and more equitable access. Our stronger presence in Mumbai strengthens our ability to work with partners across the healthcare ecosystem and advance solutions that address the needs of patients in India. Our strong workforce of nearly 5,000 colleagues across the country are united by a common ambition to follow the science, advance access to life saving therapies and help more people live better, healthier lives,” said Praveen Rao Akkinepally, country president and managing director, AstraZeneca Pharma India.
At the centre of its ambition is the organization’s unwavering focus on pioneering newer access pathways so life-saving therapies can reach every patient that needs them. Working closely with governments and industry, AstraZeneca has focused on leveraging AI and building solutions across the continuum of care – from prevention, awareness, to diagnosis and treatment, at scale. This strategic move presents several opportunities to the organization for a closer and effective partnership with a vibrant and fast-evolving healthcare ecosystem across therapy areas it is present in-oncology, biopharmaceuticals and rare disease.
Arun Krishna, non-executive director, board of AstraZeneca Pharma India and area vice president, Asia, AstraZeneca, said “India is an increasingly important contributor to AstraZeneca’s growth across Asia. The momentum of our business, the evolution of our portfolio, and the depth of talent and capabilities in the country provides a strong foundation for the opportunity ahead. Our new commercial office in Mumbai will support closer engagement with stakeholders and the continued development of our people, strengthening India’s contribution to our regional and global ambition.”
This step will also support AstraZeneca’s continued investment in talent and capability building in India, creating opportunities for professionals who are passionate about transforming healthcare through science, technology and collaboration. As the company expands, it will seek to attract and develop diverse talent across the value chain, said the company note.
Establishing a stronger footprint in Mumbai is a part of AstraZeneca’s broader purpose of advancing equitable healthcare globally. With this, India becomes one of the largest and diverse footprints of the organization around the world that supports commercial operations, site management and monitoring, technology, research and development, and global business services, said the company note.
